A
Albert F. LoBuglio
Researcher at University of Alabama at Birmingham
Publications - 169
Citations - 9931
Albert F. LoBuglio is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Radioimmunotherapy & Antibody. The author has an hindex of 54, co-authored 169 publications receiving 9570 citations. Previous affiliations of Albert F. LoBuglio include University of Alabama & Loyola University Chicago.
Papers
More filters
Journal ArticleDOI
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
Albert F. LoBuglio,Richard H. Wheeler,John M. Trang,Amy Haynes,Kim Rogers,Elizabeth B. Harvey,Lee Sun,John Ghrayeb,M. B. Khazaeli +8 more
TL;DR: This chimeric form of 17-1A mAb has an approximate 6-fold longer circulation time and appears to be substantially less immunogenic than its murine counterpart, which may provide an advantage in the clinical application of such chimeric molecules in therapeutic trials in humans.
Journal ArticleDOI
Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
Francisco Robert,Mark P. Ezekiel,Sharon A. Spencer,Ruby F. Meredith,James A. Bonner,M. B. Khazaeli,Mansoor N. Saleh,Delicia Carey,Albert F. LoBuglio,Richard H. Wheeler,Michael R. Cooper,Harlan W. Waksal +11 more
TL;DR: The most commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxicities (grade 1 to 2 in most patients).
Journal Article
Characterization of a messenger RNA polynucleotide vaccine vector
Robert M. Conry,Albert F. LoBuglio,M. Wright,L. Sumerel,M. J. Pike,F. W. Johanning,R. Benjamin,D. Lu,David T. Curiel +8 more
TL;DR: This article constructed mRNA transcripts encoding luciferase and human carcinoembryonic antigen (CEA) which are capped, polyadenylated, and stabilized by human β-globin 5′ and 3′ untranslated regions.
Journal ArticleDOI
Human immune response to monoclonal antibodies.
TL;DR: In this article, the authors discuss what is known regarding human immune response to monoclonal antibodies and their clinical consequences, and discuss the problems that need to be resolved before any such reagents can be used routinely in patients.
Journal Article
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
James A. Bonner,Kevin P. Raisch,Hoa Q. Trummell,Francisco Robert,Ruby F. Meredith,Sharon A. Spencer,Donald J. Buchsbaum,Mansoor N. Saleh,Murray A. Stackhouse,Albert F. LoBuglio,Glenn E. Peters,William R. Carroll,Harlan W. Waksal +12 more
TL;DR: Preclinical work serves as important support for the ongoing clinical investigation of C225 and radiotherapy for patients with head and neck carcinomas by indirectly linking C225/radiation-induced regulation of STAT-3 protein to apoptosis.